By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: New Data Demonstrate Sustained Long-Term Efficacy Of OFEV* On Slowing Disease Progression And Safety In Patients With IPF 9/29/2015 10:49:20 AM
Boehringer Ingelheim Release: New Data Shows OFEV (nintedanib) Efficacy Is Sustained Long-Term With No New Safety Signals In Patients With IPF 9/29/2015 7:19:39 AM
Boehringer Ingelheim Release: VARGATEF Plus Docetaxel Significantly Reduced Tumour Burden In Lung Cancer Patients With Advanced Adenocarcinoma Compared To Docetaxel Alone 9/28/2015 1:42:04 PM
Boehringer Ingelheim Release: ECC 2015: GIOTRIF (Afatinib) Demonstrates Superior Survival Compared To Tarceva (Erlotinib) For Patients With Previously Treated Advanced Squamous Cell Carcinoma Of The Lung, Independent Of EGFR Mutation Status 9/28/2015 1:40:27 PM
Boehringer Ingelheim Release: COPD: New Data Support Role Of Spiolto Respimat As 1st-Line Maintenance Therapy And Show Superiority Over LABA/ICS 9/28/2015 12:55:04 PM
Boehringer Ingelheim Release: New Head-to-Head STIOLTO RESPIMAT Data Presented At ERS Annual Congress 9/28/2015 10:38:25 AM
Boehringer Ingelheim Release: CHMP Grants Positive Opinion For Idarucizumab, The Specific Reversal Agent For Dabigatran Etexilate (Pradaxa) 9/25/2015 11:13:01 AM
Boehringer Ingelheim Release: European Medicines Agency Fast-Tracks Antidote To Anticoagulant Pradaxa 9/25/2015 8:57:15 AM
Boehringer Ingelheim Release: Extending Overall Survival Is Less Important Than Quality Of Life And Disease Stability For The Majority Of Physicians Treating Patients With Advanced Lung Cancer Following First Line-Chemotherapy 9/25/2015 8:41:59 AM
Boehringer Ingelheim: Global SAP Access With Intrexx 9/24/2015 10:05:45 AM